Mortality risk factors in febrile ulceronecrotic Mucha- Habermann disease: a systematic review of therapeutic outcomes and complications
Dermatology Reports · 21.11.2022 · 14 (4)
DOI: 10.4081/dr.2022.9492 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Dermatology Reports, online erschienen am 21.11.2022. Verfasst von Vasiliki Tasouli-Drakou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Education, College of Osteopathic Medicine, Touro University Nevada, Henderson, NV. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Febrile ulceronecrotic Mucha-Habermann Disease (FUMHD) is a variant of Pityriasis Lichenoides Et Varioliformis Acuta (PLEVA). Although rare, the condition may progress to involve serious complications and even lead to fatal outcomes if diagnosis and appropriate treatment is delayed. A PubMed search following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA) guidelines was performed to find cases of FUMHD from the earliest records to October 2021. Treatments, complications, and patient outcomes were extracted from the literature and summarized, while a review of quality was also performed. A total of 63 publications with 68 patients were found. Successful treatment modalities for FUMHD included antibiotics, antivirals, systemic steroids, methotrexate (MTX), cyclophosphamide, cyclosporine (CYA), intravenous immunoglobulins (IVIG), pentoxifylline, and ultraviolet B phototherapy. Out of 68 patients, 55 patients had their condition fully resolved and 13 cases were fatal. Increased age, systemic involvement, and monoclonal T-cell receptor rearrangement were associated with worst prognosis, but mucosal involvement did not affect mortality risk. Overall, the publications had low risk of bias, but most lacked adequate follow-up periods. FUMHD is a diagnostic and therapeutic challenge due to the lack of clearly defined diagnostic criteria and optimum treatment. Further studies with larger patient populations and longer follow-up periods may lead to refinement of diagnostic criteria, establish an optimum treatment regimen, and better estimate the likelihood of recurrence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Education, College of Osteopathic Medicine, Touro University Nevada, Henderson, NV.
- Department of Physician Assistant Studies, College of Health and Human Services, Touro University Nevada, Henderson, NV.
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Zitieren
APA
Tasouli-Drakou, V., Nguyen, M., Guinn, H., Hassan, O., Butala, S., & Phan, S. (2022). Mortality risk factors in febrile ulceronecrotic Mucha- Habermann disease: a systematic review of therapeutic outcomes and complications. Dermatology Reports, 14(4). https://doi.org/10.4081/dr.2022.9492
Vancouver
Tasouli-Drakou V, Nguyen M, Guinn H, Hassan O, Butala S, Phan S. Mortality risk factors in febrile ulceronecrotic Mucha- Habermann disease: a systematic review of therapeutic outcomes and complications. Dermatology Reports. 2022;14(4). doi:10.4081/dr.2022.9492
BibTeX
@article{TasouliDrakou2022,
author = {Tasouli-Drakou, Vasiliki and Nguyen, May and Guinn, Hannah and Hassan, Omron and Butala, Sneha and Phan, Sheshanna},
title = {Mortality risk factors in febrile ulceronecrotic Mucha- Habermann disease: a systematic review of therapeutic outcomes and complications},
journal = {Dermatology Reports},
year = {2022},
volume = {14},
number = {4},
doi = {10.4081/dr.2022.9492}
}
EUVIMED